Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Nykode Therapeutics AS's Enterprise Value is €58.30 Mil.
Nykode Therapeutics AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was €-24.70 Mil. Therefore, Nykode Therapeutics AS's EV-to-OCF for today is -2.36.
The historical rank and industry rank for Nykode Therapeutics AS's EV-to-OCF or its related term are showing as below:
FRA:5VB'
s EV-to-OCF Range Over the Past 10 Years
Min: -40.31 Med: 0.24 Max: 1282.23
Current: -2.18
During the past 9 years, the highest EV-to-OCF of Nykode Therapeutics AS was 1282.23. The lowest was -40.31. And the median was 0.24.
FRA:5VB's EV-to-OCF is ranked worse than 57.32% of 1408
companies
in the Biotechnology industry
Industry Median: -3.53
vs FRA:5VB: -2.18
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nykode Therapeutics AS (FRA:5VB) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nykode Therapeutics AS's PE Ratio (TTM) for today is calculated as:
Nykode Therapeutics AS's share price for today is €0.26.
Nykode Therapeutics AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.035.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nykode Therapeutics AS's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nykode Therapeutics AS EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Nykode Therapeutics AS's EV-to-OCF falls into.
Nykode Therapeutics AS's current Enterprise Value is €58.30 Mil.
Nykode Therapeutics AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-24.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nykode Therapeutics AS (FRA:5VB) has a EV-to-OCF of -2.36 as of Aug. 13, 2026. According to the industry distribution chart, Nykode Therapeutics AS ranks #807 out of 1408 companies in the Biotechnology industry, placing it in the top 57.3%.
Is Nykode Therapeutics AS's EV-to-OCF too high?
Nykode Therapeutics AS's current EV-to-OCF is -2.36. Based on the distribution chart, Nykode Therapeutics AS ranks #807 out of 1408 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nykode Therapeutics AS has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nykode Therapeutics AS ranks #807 out of 1408 companies for EV-to-OCF. This places Nykode Therapeutics AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Nykode Therapeutics AS's current EV-to-OCF is -2.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (FRA:5VB) is currently considered Possible Value Trap. The stock's GF Value™ is €0.70, compared to a current price of €0.26 — trading 62.9% below its estimated fair value. The current EV-to-OCF is -2.36. Nykode Therapeutics AS's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Nykode Therapeutics AS (FRA:5VB), the current EV-to-OCF is -2.36 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nykode Therapeutics AS (FRA:5VB) Overvalued in 2026?
Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued.
The current stock price of €0.26 is trading 62.9% below its estimated GF Value™ of €0.70.
GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.
Key valuation signals for FRA:5VB:
EV-to-OCF: -2.36
GF Value™: €0.70 vs. price of €0.26 (62.9% below fair value)
No single metric tells the full story. See the FRA:5VB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
48GF Score
Get the complete analysis for FRA:5VB
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5VB has been successfully added to your 
